DE69839821D1 - Neue sulfonamid-substituierte chroman-derivate verwendbar als beta 3 adrenorezeptor agonisten - Google Patents

Neue sulfonamid-substituierte chroman-derivate verwendbar als beta 3 adrenorezeptor agonisten

Info

Publication number
DE69839821D1
DE69839821D1 DE69839821T DE69839821T DE69839821D1 DE 69839821 D1 DE69839821 D1 DE 69839821D1 DE 69839821 T DE69839821 T DE 69839821T DE 69839821 T DE69839821 T DE 69839821T DE 69839821 D1 DE69839821 D1 DE 69839821D1
Authority
DE
Germany
Prior art keywords
adrene
beta
receptor agonists
chroman derivatives
substituted chroman
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69839821T
Other languages
English (en)
Inventor
Gaetan H Ladouceur
Richard D Connell
Jeremy Baryza
Ann-Marie Campbell
Timothy G Lease
James H Cook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Application granted granted Critical
Publication of DE69839821D1 publication Critical patent/DE69839821D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69839821T 1997-12-19 1998-11-17 Neue sulfonamid-substituierte chroman-derivate verwendbar als beta 3 adrenorezeptor agonisten Expired - Fee Related DE69839821D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99458597A 1997-12-19 1997-12-19
PCT/US1998/024627 WO1999032475A1 (en) 1997-12-19 1998-11-17 Novel sulfonamide substituted chroman derivatives useful as beta-3 adrenoreceptor agonists

Publications (1)

Publication Number Publication Date
DE69839821D1 true DE69839821D1 (de) 2008-09-11

Family

ID=25540825

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69839821T Expired - Fee Related DE69839821D1 (de) 1997-12-19 1998-11-17 Neue sulfonamid-substituierte chroman-derivate verwendbar als beta 3 adrenorezeptor agonisten

Country Status (12)

Country Link
EP (1) EP1054881B1 (de)
JP (1) JP2001526281A (de)
AR (1) AR016691A1 (de)
AT (1) ATE402933T1 (de)
AU (1) AU751015B2 (de)
CA (1) CA2314925A1 (de)
CO (1) CO4990952A1 (de)
DE (1) DE69839821D1 (de)
IL (1) IL136688A0 (de)
TW (1) TW502032B (de)
WO (1) WO1999032475A1 (de)
ZA (1) ZA9810489B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000256331A (ja) * 1999-01-08 2000-09-19 Nippon Bayer Agrochem Co Ltd テトラゾリノン誘導体および除草剤としてのその用途
DE60015036T2 (de) * 1999-07-23 2006-03-02 Pfizer Products Inc., Groton Zwischenprodukte und ein Verfahren zur Herstellung von beta3-Adrenergischer Rezeptor-Agoniste
BR0112409A (pt) * 2000-07-13 2003-07-22 Lilly Co Eli Agonistas para beta3 adrenérgico
CZ20013076A3 (cs) 2000-08-29 2002-04-17 Kuraray Co., Ltd. Způsob výroby chromankarboxylové kyseliny
JP2005505586A (ja) 2001-10-04 2005-02-24 ワイス ５−ヒドロキシトリプタミン−６リガンドとしてのクロマン誘導体
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
US7034051B2 (en) 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
US20050222247A1 (en) * 2003-12-13 2005-10-06 Bayer Healthcare Ag Chroman derivatives
US20120135997A1 (en) 2009-07-17 2012-05-31 Shionogi & Co., Ltd. Pharmaceutical composition comprising a lactam or benzenesulfonamide compound
EP2536693A4 (de) * 2010-02-17 2014-08-06 UNIVERSITé LAVAL Substituierte 2-imidazolidone und analoga
CN108218845B (zh) * 2016-12-21 2022-11-29 江苏柯菲平医药股份有限公司 一类色满-6-磺酰胺RORγ调节剂及其用途
CN112107583A (zh) * 2020-07-31 2020-12-22 东南大学 一种色满-6-磺酰胺RORγ调节剂的A晶型化合物的组合物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091749A3 (de) * 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
IL113410A (en) * 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
US5663194A (en) * 1995-07-25 1997-09-02 Mewshaw; Richard E. Chroman-2-ylmethylamino derivatives
FR2746395B1 (fr) * 1996-03-22 1998-04-17 Adir Nouveaux derives d'arylethanolamine et d'aryloxypropanolamine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0801060A1 (de) * 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclische Beta-3 adrenergische Angonisten

Also Published As

Publication number Publication date
EP1054881A1 (de) 2000-11-29
ZA9810489B (en) 1999-05-20
EP1054881B1 (de) 2008-07-30
AR016691A1 (es) 2001-07-25
ATE402933T1 (de) 2008-08-15
TW502032B (en) 2002-09-11
CA2314925A1 (en) 1999-07-01
JP2001526281A (ja) 2001-12-18
AU1418399A (en) 1999-07-12
WO1999032475A1 (en) 1999-07-01
CO4990952A1 (es) 2000-12-26
AU751015B2 (en) 2002-08-08
IL136688A0 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
DE69525857T2 (de) Östrogen-agonisten/antagonisten
NO982589L (no) 3-pyrazol-karboksamid-derivater med cannabinoid reseptor-affinitet
EP0979228A4 (de) Cannabinoid-rezeptor agonisten
DE69926861D1 (de) Beta 2- adrenergische rezeptoragonisten
DE69832486D1 (de) C-4"-substitutierte macrolid-derivate
BR9711970A (pt) Derivados 6,5-substitu¡do-heterobic¡clicos
DE69728392D1 (de) Indolderivate verwendbar als endothelinrezeptorantagonisten
ATE226212T1 (de) 2-(purin-9-)-tetrahydrofuran-3,4-diol-derivate
ATE184015T1 (de) Neue 19-nor-pregnen-derivate
DE69528197T2 (de) Neue 1,3-dialkylharnstoff-derivate
IS5402A (is) Útskiptar króman afleiður
DK0708105T3 (da) 5-HT4-receptoragonister
ID21009A (id) Komposisi untuk supositori
DE69839821D1 (de) Neue sulfonamid-substituierte chroman-derivate verwendbar als beta 3 adrenorezeptor agonisten
IS5403A (is) Útskiptar króman afleiður
DK0906294T3 (da) Benzoxazinon-dopamin D4-receptor-antagonister
ID17561A (id) Komposisi untuk pemakaian luar
DE69521883D1 (de) Aromatische 2-amino-imidazolderivate als alpha 2a-adrenoceptor agonisten
DE69703242D1 (de) Indolin-derivate verwendbar als 5-ht-2c rezeptor-antagonisten
ATE215551T1 (de) Neue pyranosidderivate
DE69717449T2 (de) Indolin-derivate verwendbar als 5-ht-2c rezeptor-antagonisten
FI971854A (fi) Substituoituja tetrasyklisiä atsepiinijohdannaisia, joilla on 5-HT2-reseptoriaffiniteetti
NO996391D0 (no) Angiogenese-inhiberende tiadiazolylpyridazinderivater
ATE223380T1 (de) Heteroaryloxyethylaminen als 5-ht1a rezeptor liganden
FI972558A0 (fi) Uusi reseptori

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee